Treatment for Iron Deficiency Anemia in Pregnancy
For confirmed iron deficiency anemia in pregnancy, treat with oral elemental iron 60-120 mg daily as first-line therapy, reserving intravenous iron for patients who cannot tolerate, cannot absorb, or do not respond to oral iron. 1
Diagnostic Approach
Screen all pregnant women with a complete blood count in the first trimester and again at 24-28 weeks gestation. 2 Initial screening uses hemoglobin or hematocrit measurement:
- Anemia thresholds: Hemoglobin <11.0 g/dL in first trimester, <10.5-11.0 g/dL in second/third trimester 2
- Mild anemia (Hgb ≥10.0 g/dL) with mildly low or normal MCV likely represents iron deficiency—proceed directly to oral iron trial 2
- Further workup needed for: Very low MCV, macrocytic anemia, moderate anemia (Hgb 7.0-9.9 g/dL), or severe anemia (Hgb 4.0-6.9 g/dL) 2
Treatment Algorithm
First-Line: Oral Iron Therapy
Dosing: 60-120 mg elemental iron daily 1
Key practical points:
- Recent evidence supports intermittent dosing (alternate days) as equally effective as daily dosing with fewer gastrointestinal side effects 2
- Prenatal vitamins typically contain only 30 mg elemental iron—insufficient for treating established anemia 1
- Higher doses (60-100 mg daily) should be prescribed for populations at increased risk 1
Common side effects: Gastrointestinal symptoms (nausea, constipation, epigastric discomfort), darkening of urine/stool, teeth/gum staining 1, 3
Second-Line: Intravenous Iron Therapy
- Intolerance to oral iron (significant GI side effects)
- Malabsorption (e.g., inflammatory bowel disease, celiac disease, prior gastric surgery)
- Non-response to adequate oral iron trial
- Severe anemia requiring rapid correction
- Late presentation in pregnancy with insufficient time for oral repletion
Advantages demonstrated in recent high-quality evidence: A 2026 meta-analysis of 29 RCTs (11,771 participants) showed IV iron compared to oral iron resulted in 5:
- Higher maternal hemoglobin at delivery (0.59 g/dL increase)
- Higher maternal ferritin at delivery (50.93 ng/mL increase)
- 37% reduction in blood transfusion rates (RR 0.63), particularly in those with pretreatment Hgb ≤9 g/dL (RR 0.58)
- Higher neonatal ferritin levels (21.38 ng/mL increase)
- 43% fewer mild adverse effects compared to oral iron (RR 0.56)
- No serious adverse events reported
Formulations: Ferric carboxymaltose shows practical and hematologic advantages over iron sucrose in head-to-head trials 3
Safety considerations:
- Contemporary IV iron formulations have rare allergic reactions 2
- Monitor for hypophosphatemia with newer IV iron agents 6
- Safety in first trimester requires further evaluation—use with caution 6
- Distinguish true hypersensitivity from complement activation-related pseudoallergy 6
Risk Factors Requiring Higher Vigilance
Identify patients at increased risk for iron deficiency 1:
- Dietary: Vegetarian/vegan diet (nonheme iron less well-absorbed; may need nearly double the iron intake)
- Medical: Gastrointestinal disease, medications reducing iron absorption (antacids)
- Obstetric: Short interpregnancy interval, multiparity (≥2 pregnancies)
- Demographic: Non-Hispanic Black and Mexican American women have higher prevalence
Dietary Supplementation
The Institute of Medicine recommends 27 mg iron daily during pregnancy 1. Natural sources include:
- Heme iron (better absorbed): Meat, poultry
- Nonheme iron: Fruits, vegetables, fortified breads/cereals (>50% of U.S. iron supply comes from fortified grain products)
Critical Clinical Caveats
Important nuances:
- While observational studies suggest associations between maternal anemia and adverse outcomes (postpartum hemorrhage, preterm birth, low birthweight), findings remain inconclusive regarding causality 1
- The largest pragmatic trials from resource-limited settings showed biochemical superiority of IV iron did not consistently translate to improved major maternal/neonatal outcomes 3
- Avoid overtreatment: Physiologic hemodilution in pregnancy can mimic anemia—confirm true iron deficiency before treating 7
- Both very low AND very high maternal hemoglobin levels may associate with unfavorable outcomes 7
When to escalate: If moderate-to-severe anemia persists despite appropriate oral iron therapy, or if rapid correction is needed with limited time before delivery, proceed to IV iron rather than continuing ineffective oral therapy 3, 2